Clinical Trial

China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Study acronym: DREAMM 7
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Chinese participants with relapsed/refractory multiple myeloma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-06; most recent amendment 2026-04-03.
Trial Details
NCT Number NCT06868654
Lead Sponsor GlaxoSmithKline
Conditions Multiple Myeloma
Enrollment 72 participants
Start Date 2021-07-28
Primary Completion 2024-04-03 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-23